Anti-β-Gal monoclonal antibody for ADC

Monoclonal human IgG1 antibody against β-galactosidase for antibody-drug conjugation

InvivoGen provides Anti-β-Gal-hIgG1*, a monoclonal antibody (mAb) specifically developed for the generation of control antibody-drug conjugates (ADCs). This mAb features:

• the variable region of a murine mAb which specifically targets the E. coli β-galactosidase (β-Gal),
• a human IgG1 constant region that displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).

InvivoGen's Anti-β-Gal-hIgG1* has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.

Key features of Anti-β-Gal-hIgG1*:

• No binding to any other antigen than β-Gal, as verified by ELISA, flow cytometry, and ADC-based cellular assays
• Human IgG1 constant region for high effector functions
• The absence of bacterial contamination has been confirmed

Application for Anti-β-Gal-hIgG1*:

• Negative control for ADC-based assays
   

InvivoGen offers Anti-HER2-IgG1 and Anti-TROP2-hIgG1 specific mAbs, as well as conjugatable PRR ligands for building immunostimulatory ADCs.
You may choose from TLR7 and STING agonists:
- Conjugatable TLR7 agonists: TL7-887 and TL7-975
- Conjugatable STING agonists: STG-982 and STG-968

Learn more about bioconjugation

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

Figures

Anti-β-hIgG1* mAb binding to plate-bound β-galactosidase. β-galactosidase protein (2 μg/ml) was coated on ELISA plates overnight. A 3-fold serial dilution of Anti-β-Gal-hIgG1* (red curve) or of Anti-hCD20-hIgG1 control mAb (grey curve) was realized for the capture step. An HRP-labelled anti-human IgG1 (1/1000 dilution) and the HRP substrate OPD (o-phenylenediamine dihydrochloride) were used for the detection step. Absorbance was read at 490 nm.

Absence of Anti-β-hIgG1* mAb binding to EL4-hCD20 cells. ~5 x 10⁵ EL4 cells stably expressing cell surface human CD20 antigen were incubated with 2 µg of Anti-β-Gal-hIgG1* mAb or Anti-hCD20-hIgG1 control mAb for 45 min at 4°C. Cells were then washed and incubated with 250 ng of goat anti-human κ light chain antibody coupled to PE for 1h at 4°C. Cell surface staining was analyzed by flow cytometry.

Dose-response of human PBMCs co-cultured with BxPC-3 tumor cells and Anti-TROP2/STG-982 or Anti-β-Gal/STG-982 ADC. 1.5x10⁵ human PBMCs and 5x10⁴ BxPC-3 TROP2⁺ tumor cells (A) or 1.5x10⁵ human PBMCs only (B) were incubated with increasing concentrations of Anti-TROP2/STG-982 ADC (DAR ~4), Anti-β-Gal/STG-982 ADC (DAR ~4), or STG-982 only. After overnight incubation, the STING-mediated response was assessed by measuring the production of CXCL10 in PBMC and BxPC-3 co-culture supernatants, using an ELISA. The optical density (OD) at 450 nm is shown.

Specifications

Specificity: Targets E. coli β-galactosidase

Isotype: Human IgG1, Kappa

Source: Chinese hamster ovary (CHO) cells 

Formulation: 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose

Purification: Affinity chromatography with protein A

Tested Applications: Flow cytometry, ELISA, Antibody-drug conjugation

Quality control:

• The binding of Anti-β-Gal-hIgG1* to β-galactosidase has been validated using ELISA.
• The absence of non-specific binding of Anti-β-Gal-hIgG1* has been validated using flow cytometry and antibody-drug conjugate (ADC)-based cellular assays.
• The complete sequence of the antibody has been verified.
• The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ hTLR2 and HEK-Blue™ TLR4 cellular assays.

Contents

• 1 mg of purified Anti-β-Gal-hIgG1* monoclonal antibody (mAb), provided azide-free and lyophilized

 The product is shipped at room temperature.

 Store lyophilized antibody at -20 °C.

 Lyophilized product is stable for at least 1 year. Reconstituted antibody is stable for 1 month at 4°C and for 1 year at -20°C. Avoid repeated freeze-thaw cycles.